Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study

• Published in: Psychological medicine Vol. 45; no. 8; pp. 1641 - 1652
• Main Authors: Kim, J.-M., Stewart, R., Bae, K.-Y., Kang, H.-J., Kim, S.-W., Shin, I.-S., Hong, Y. J., Ahn, Y., Jeong, M. H., Yoon, J.-S.
• Format: Journal Article
• Language: English
• Published: Cambridge, UK Cambridge University Press 01.06.2015
• Subjects: Acute Coronary Syndrome - epidemiology; Acute Coronary Syndrome - psychology; Citalopram - therapeutic use; Comorbidity; Depressive Disorder - drug therapy; Depressive Disorder - epidemiology; Depressive Disorder - psychology; Double-Blind Method; Female; Heart attacks; Humans; Longitudinal Studies; Male; Mental depression; Middle Aged; Original Articles; Quality of life; Quality of Life - psychology; Serotonin Uptake Inhibitors - therapeutic use; Treatment Outcome; longitudinal study; depression; Acute coronary syndrome; quality of life; randomized controlled trial
• ISSN: 0033-2917; 1469-8978
• DOI: 10.1017/S003329171400275X

Depression is common after acute coronary syndrome (ACS) with adverse effects on prognosis. There is little evidence on whether depression treatment improves quality of life (QoL) in ACS patients. The aim of this study was to investigate the effects of co-morbid depression and its treatment on QoL in ACS. In total, 1152 patients were recruited at baseline, 2-14 weeks after a confirmed ACS episode, and 828 were followed 1 year thereafter. Of 446 baseline participants with co-morbid depressive disorders, 300 were randomized to a 24-week double blind trial of escitalopram or placebo, while the remaining 146 received medical treatment only (MTO). QoL was measured by the World Health Organization Quality of Life -Abbreviated form (WHOQOL-BREF). At baseline, QoL was significantly lower in patients with co-morbid depressive disorder than those without. QoL improvement was significantly greater in those receiving escitalopram than those receiving placebo over the 24-week treatment period. In the 1-year follow-up, the better outcomes associated with escitalopram remained evident against both placebo and MTO. Depression was significantly associated with worse QoL even in patients with recently developed ACS. Depression treatment was associated with QoL improvement in ACS patients in the 24-week treatment period, the effects of which extended to 1 year.